Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma

التفاصيل البيبلوغرافية
العنوان: Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma
المؤلفون: Ania Henning, Doreen M. Agnese, Catherine Chung
المصدر: Journal of Cutaneous Pathology. 48:1423-1426
بيانات النشر: Wiley, 2021.
سنة النشر: 2021
مصطلحات موضوعية: CD20, education.field_of_study, Pathology, medicine.medical_specialty, Histology, biology, business.industry, Melanoma, medicine.medical_treatment, Population, Dermatology, Immunotherapy, medicine.disease, Pathology and Forensic Medicine, Oncolytic virus, biology.protein, medicine, Stage IIIC, Histopathology, Talimogene laherparepvec, education, business
الوصف: Talimogene laherparepvec (TVEC) is a genetically modified herpes simplex virus-1 approved as an intralesional oncolytic immunotherapy for the treatment of advanced melanoma. Cutaneous reactions at the site of injection may mimic recurrent or progressive melanoma; histopathological findings have included chronic granulomatous dermatitis, neutrophilic dermatitis, lymphocytic dermatitis, and pigment incontinence. We report a 39-year-old male with metastatic stage IIIc melanoma treated with TVEC with clinical regression of melanoma lesions that later developed pink nodules at sites of prior injection. Histopathology demonstrated a nodular mononuclear infiltrate that stained strongly and diffusely with CD45 and CD20 with a surrounding rim of CD3-positive T-cells. Immunoglobulin gene rearrangement was negative for a clonal B-cell population. To our knowledge, this is the first report of a pseudolymphomatous reaction mimicking recurrent melanoma after TVEC therapy.
تدمد: 1600-0560
0303-6987
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b1160afd946d3981a98f34123c028c3e
https://doi.org/10.1111/cup.14094
حقوق: CLOSED
رقم الأكسشن: edsair.doi...........b1160afd946d3981a98f34123c028c3e
قاعدة البيانات: OpenAIRE